PYXS

0.9568

4.97% 0.0453

Handel nachbörslich: 1.00 0.0432 +4.52%

Pyxis Oncology Inc (PYXS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt PYXS? Forum Prognose

Schlusskurs vom Vortag:

$0.9115

Offen:

$0.883

24-Stunden-Volumen:

618.04K

Relative Volume:

1.03

Marktkapitalisierung:

$56.14M

Einnahmen:

Nettoeinkommen (Verlust:

$-73.79M

KGV:

-0.52

EPS:

-1.84

Netto-Cashflow:

$-77.44M

1W Leistung:

-2.36%

1M Leistung:

-17.52%

6M Leistung:

-71.86%

1J Leistung:

-82.48%

1-Tages-Spanne:

$0.8332

$0.9762

1-Wochen-Bereich:

$0.8332

$1.03

52-Wochen-Spanne:

$0.8332

$5.74

Pyxis Oncology Inc Stock (PYXS) Company Profile

Firmenname

Pyxis Oncology Inc

Sektor

Healthcare (1163)

Branche

Biotechnology (681)

Telefon

(617) 221-9059

Adresse

321 HARRISON AVENUE, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-08-11

Neueste SEC-Einreichungen

PYXS's Discussions on Twitter

Vergleichen Sie PYXS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PYXS Pyxis Oncology Inc	0.9568	56.14M	0	-73.79M	-77.44M	-1.84
VRTX Vertex Pharmaceuticals Inc	474.56	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	572.78	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	550.00	33.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.95	30.15B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	220.54	25.69B	3.81B	-644.79M	-669.77M	-6.24

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-21	Herabstufung	William Blair	Outperform → Mkt Perform
2024-11-08	Eingeleitet	Stephens	Overweight
2024-08-08	Eingeleitet	Stifel	Buy
2024-05-07	Fortgesetzt	Jefferies	Buy
2024-02-09	Eingeleitet	BTIG Research	Buy
2024-01-23	Eingeleitet	Leerink Partners	Outperform
2023-09-05	Eingeleitet	RBC Capital Mkts	Outperform
2021-11-02	Eingeleitet	BofA Securities	Neutral
2021-11-02	Eingeleitet	Credit Suisse	Outperform
2021-11-02	Eingeleitet	Jefferies	Buy

Alle ansehen

Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten

Apr 07, 2025

Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com India

Apr 07, 2025

Apr 04, 2025

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

Apr 04, 2025

Apr 02, 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025

Mar 31, 2025

Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada

Mar 31, 2025

Mar 26, 2025

Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News

Mar 26, 2025

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times

Mar 26, 2025

Mar 25, 2025

Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener

Mar 25, 2025

Breakthrough Cancer Drug Achieves Major Milestones: FDA Fast-Tracks Pyxis's Revolutionary Tumor Treatment - Stock Titan

Mar 25, 2025

Mar 24, 2025

Pyxis Oncology Highlights Strategic Focus on Lead Candidate - TipRanks

Mar 24, 2025

Mar 23, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Mar 23, 2025

Mar 22, 2025

Analysts Set Expectations for Pyxis Oncology Q1 Earnings - Defense World

Mar 22, 2025

HC Wainwright Expects Stronger Earnings for Pyxis Oncology - Defense World

Mar 22, 2025

Mar 21, 2025

Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World

Mar 21, 2025

Optimistic Buy Rating for Pyxis Oncology Amid Strategic Focus and Promising Drug Developments - TipRanks

Mar 21, 2025

William Blair Weighs in on Pyxis Oncology FY2027 Earnings - Defense World

Mar 21, 2025

HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - Defense World

Mar 21, 2025

Mar 19, 2025

Pyxis Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 19, 2025

RBC Capital Remains a Buy on Pyxis Oncology (PYXS) - The Globe and Mail

Mar 19, 2025

Mar 18, 2025

Pyxis Oncology Advances Cancer Therapeutics with MICVO - TipRanks

Mar 18, 2025

Jefferies cuts Pyxis Oncology target to $6, maintains Buy By Investing.com - Investing.com Australia

Mar 18, 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025

Pyxis Oncology Reports Promising Phase 1 Data for MICVO in Head and Neck Cancer, Receives FDA Fast Track Designation - Nasdaq

Mar 18, 2025

Empress Therapeutics confirms layoffs; Nanobiotix amends J&J deal terms - Endpoints News

Mar 18, 2025

Mar 17, 2025

Pyxis Oncology Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView

Mar 17, 2025

Mar 13, 2025

Pyxis Oncology (PYXS) to Release Earnings on Thursday - Defense World

Mar 13, 2025

Mar 12, 2025

Closing Figures Unveiled: Pyxis Oncology Inc (PYXS) Drop -2.80, Closes at 1.04 - The Dwinnex

Mar 12, 2025

Mar 03, 2025

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times

Mar 03, 2025

Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan

Mar 03, 2025

Feb 27, 2025

FDA Grants PYX-201 Fast Track Status in HNSCC - Targeted Oncology

Feb 27, 2025

Feb 26, 2025

Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire

Feb 26, 2025

Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St

Feb 26, 2025

Pyxis Oncology rises on FDA fast track tag for lead asset - MSN

Feb 26, 2025

Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com

Feb 26, 2025

FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada

Feb 26, 2025

Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq

Feb 26, 2025

PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan

Feb 26, 2025

FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India

Feb 26, 2025

Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha

Feb 26, 2025

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - The Manila Times

Feb 26, 2025

Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq

Feb 26, 2025

Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan

Feb 26, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Feb 26, 2025

Feb 25, 2025

Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World

Feb 25, 2025

Feb 24, 2025

Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa

Feb 24, 2025

Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada

Feb 24, 2025

Feb 23, 2025

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance

Feb 23, 2025

Feb 18, 2025